A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.


Journal Article

In a randomized multi-center study, 83 patients with small cell lung cancer were randomly assigned to treatment with cisplatin 100 mg/m2 intravenously (IV) day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3 or cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3. Both regimens were repeated every 4 weeks. Prior to randomization, patients were stratified by extent of disease, performance status, and gender. A total of 41 patients were randomly assigned to the parenteral treatment only regimen, and 42 patients received cisplatin and IV/oral etoposide therapy. Both treatment arms were comparable regarding patient characteristics. Limited disease (LD) patients constituted 52% and 49% of the patient population for the oral and IV etoposide regimens, respectively. The overall complete response (CR) and partial response (PR) rate was 50% (95% confidence interval [CI] 35% to 65%) for the oral etoposide regimen and 59% (95% CI 44% to 74%) for the IV etoposide regimen (P = 0.438). For both regimens, 55% of the LD patients achieved either CR or PR. Time to progression and survival were comparable for both treatment arms. Hematologic toxicity was comparable in both treatment arms, with 80% of patients experiencing grade 3 or 4 neutropenia or thrombocytopenia. Moderate to severe anemia and weight loss were more predominant with the IV than with the oral regimen.

Full Text

Duke Authors

Cited Authors

  • Johnson, DH; Ruckdeschel, JC; Keller, JH; Lyman, GH; Kallas, GJ; Macdonald, J; DeConti, RC; Lee, J; Ringenberg, QS; Patterson, WP

Published Date

  • January 1, 1991

Published In

Volume / Issue

  • 67 / 1 Suppl

Start / End Page

  • 245 - 249

PubMed ID

  • 1845847

Pubmed Central ID

  • 1845847

International Standard Serial Number (ISSN)

  • 0008-543X

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19910101)67:1+<245::aid-cncr2820671306>3.0.co;2-z


  • eng

Conference Location

  • United States